Highlights Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Real-time Estimate Cboe BZX Other stock markets 12:43:41 2024-05-07 pm EDT			5-day change	1st Jan Change
12.65 ^USD	-1.56%		+6.74%	+35.25%

Mar. 28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Reverse Split: 1 of 12	Feb. 11	FA
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	Jan. 04	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies	23-10-17	MT
Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration	23-10-17	DJ
Gilead Sciences, Inc. and Assembly Biosciences, Inc. Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases	23-10-17	CI
Assembly Biosciences Nominates Development Candidate Abi-6250, an Orally Bio Available HDV Entry Inhibitor	23-10-02	CI
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	23-09-19	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Assembly Biosciences, Inc. Presents New Data Highlighting Herpes Simplex Virus Development Candidate Abi-5366 At the 47Th Annual International Herpesvirus Workshop	23-07-17	CI
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Assembly Biosciences Announces Additional Promising Data from Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334 and Provides Pipeline Update	23-04-18	CI
Assembly Biosciences, Inc. Provides Update on its Core Inhibitor Pipeline	23-03-22	CI
Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes	23-02-15	CI
Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334	22-12-19	CI
Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334	22-11-14	CI
Earnings Flash (ASMB) ASSEMBLY BIOSCIENCES Posts Q3 Loss $-0.48	22-11-08	MT
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV	22-11-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Highlights

Filters